Learn Why The Bull Case For Inspire Medical Systems (INSP) Could Change Following Shareholder Investigation

• Inspire Medical Systems reported that in October 2026 a law firm began investigating alleged misleading statements around Inspire V demand, provider inventory, launch readiness, and Medicare reimbursement and CPT coding, while the AMA had already approved new Category I CPT codes for Inspire V scheduled to take effect in 2028.
• The combination of future CPT clarity for Inspire V and current legal scrutiny around how reimbursement and launch conditions were described places execution, governance, and coding economics at the center of Inspire Medical Systems' operating story.
• This analysis will examine how Inspire Medical Systems' investment narrative is tested by legal probes into Inspire V launch and reimbursement communication.

Compare how Inspire Medical Systems handles reimbursement and coding risk with a curated group of healthcare stocks facing similar pressures in our 34 healthcare AI stocks.

Inspire Medical Systems Investment Narrative Recap

To own Inspire Medical Systems, you need to believe the Inspire V platform and related digital tools can support a steady flow of obstructive sleep apnea procedures once coding friction eases. The immediate swing factor is execution on training, contracting, and coding education. The recent legal probe adds noise but does not change the operational work that still needs to be done.

The biggest near term catalyst remains reimbursement clarity and procedure normalization into 2027 and beyond. The main risk is that coding complexity, WISeR disruption, and legal scrutiny together keep volumes and margins under pressure for longer, especially if physicians or facilities become more cautious while questions around reimbursement communication are addressed.

The AMA decision to approve new Category I CPT codes for Inspire V, scheduled to start in January 2028, is the clearest operational signal tied to this situation. It sets a defined timetable for CMS to value these procedures and for specialty societies such as AAO HNS to input data on physician time, practice costs, and complexity.

For investors, the link to current concerns is practical. Clearer CPT descriptions for Inspire V can reduce coding disputes and make payer policies easier to apply. This directly affects the same reimbursement and Medicare questions that now face legal scrutiny. Execution risk does not disappear, but the process around coding, surveys, and RUC recommendations provides a visible framework for how reimbursement decisions will be made.

Inspire Medical Systems' current set of analyst assumptions points to revenues of US$991.6 million and earnings of US$74.2 million by 2029. This profile is based on forecast revenue expansion of 3.3% per year and a projected earnings decline of US$60.8 million from US$135.0 million today.

Uncover why Inspire Medical Systems' fair value indicates a 7% potential downside to its current price, resulting in a valuation premium that leaves little room for error.

Exploring Other Perspectives

One alternate view treats the AMA decision on new CPT codes as a powerful long term catalyst for Inspire Medical Systems, rather than just a clean up of current friction. The most optimistic analysts were already projecting about US$999.1 million of revenue and US$91.5 million of earnings by 2029. Those expectations came before this legal investigation, so your own take on coding, reimbursement and governance may lead you to explore very different scenarios.

Explore 5 other Inspire Medical Systems fair value estimates, including one that suggests as much as 293% upside from the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Inspire Medical Systems research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• See our latest analysis for Inspire Medical Systems. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Inspire Medical Systems' overall financial health at a glance.

Looking For More Ideas Beyond Inspire Medical Systems?

If the Inspire Medical Systems story leaves you wanting a wider watchlist, it can help to line it up against other businesses with clear financial traits and different risk profiles.

• Prefer cash rich balance sheets and fewer surprises around debt or liquidity events? Start with a list of solid balance sheet and fundamentals (25 results) that meet those criteria.
• If downside protection matters most to you, filter for companies with steadier risk profiles using our 31 resilient stocks with low risk scores.
• For investors hunting for overlooked opportunities with strong fundamentals, the 20 high quality undiscovered gems can surface ideas that are not yet widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com